ERBB2 and neoplasm: This is particularly notable for advanced “HER2-low” BC, in which trastuzumab-deruxtecan (T-DXD) showed anti-tumor activity in DESTINY-Breast04 trial, demonstrating that even a low to moderate HER2 expression is sufficient to obtain a therapeutic response, thereby opening a new therapeutic option (5–7).